摘要
小分子酪氨酸激酶抑制剂的出现，开启了胃肠间质瘤（GIST）的靶向治疗时代，明显改善了晚期GIST患者的客观疗效和生活质量。然而，随着治疗时间延长，耐药现象越来越普遍，并直接影响到了患者的生存。本文就当前 GIST 治疗的共识和文献，探讨经历多线靶向治疗失败后的临床应对办法。
The emergence of small molecular tyrosine kinase inhibitors opened the era of targeted therapy of gastrointestinal stromal tumor （GIST）. Survival and life of quality of patients from advanced stage are significantly improved by using targeted therapy. However, with prolonged treatment, drug resistance is becoming more and more common and directly affects the survival of patients. The current clinical management in failure of multi-line targeted therapies will be discussed in this article.
出处
《中华胃肠外科杂志》
CAS
CSCD
北大核心
2015年第4期325-327,共3页
Chinese Journal of Gastrointestinal Surgery
关键词
胃肠间质瘤
靶向治疗
耐药
Gastrointestinal stromal tumors
Targeted therapy
Drug-resistance
